EMEA recommends new contraindication for aliskiren (Rasilez): angioedema
According to the EMEA, aliskiren (Rasilez, Tekturna in the USA) should not be prescribed in patients that experienced angioedema after taking the drug. Some excerpts from the EMEA press release dated 19 February, 2009: The European Medicines Agency (EMEA) has recommended adding a contraindication to the Product Information for aliskiren, stating that it must not […]
Aliskiren (Rasilez) for essential hypertension: not recommended by the NHS Scotland
The Scottish Medicines Consortium issued on 5th December 2008 an advice on aliskiren (Rasilez, Tekturna in the US): Aliskiren (Rasilez) is not recommended for use within NHS Scotland for the treatment of essential hypertension. Aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, though its effects on mortality and […]